Pancreatic cancer is one of the deadliest forms of cancer, largely because it’s so difficult to catch early. By the time it’s ...

Mainz Biomed N.V. (“Mainz Biomed”) , a molecular genetics diagnostic company specializing in the early detection of cancer, ...

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer Discovery Analysis Demonstrates Transformative Sensitivity of 95% ...

Mainz Biomed has the exclusive rights to develop a test for early pancreatic cancer detection using Liquid Biosciences' biomarkers.

Mainz Biomed (MYNZ) announced it has entered into a License and Option Agreement with Liquid Biosciences to access a portfolio of novel mRNA ...

Furthermore, existing biomarkers, such as CA19-9, are not reliable on their own to detect early-stage pancreatic cancer. Goel, Xu, and colleagues explored the potential of an exosome-based liquid ...

A new blood test could diagnose pancreatic cancer ... As with most types of cancer, once the tumor has spread, it becomes much harder to successfully treat. “Liquid biopsy” tests which use ...

Scientists at Oregon Health and Science University (OHSU) have developed a new blood test for pancreatic cancer, one of the ... endoscopic ultrasound and other liquid biopsy tests that require ...